Christchurch Medicines Information Service

Sacubitril + valsartan is now available in New Zealand and fully subsidised under Special Authority criteria. Eligible patients must have NYHA/WHO functional class II, III or IV heart failure; a left ventricular ejection fraction of <35%; and be receiving standard heart failure therapy. It can...

Compliance packs With an ageing population there is increasing incidence of multimorbidity and polypharmacy. This leads to complex dosing regimens. Compliance aids, such as the Medico Paks® or unit dose medication sachets, are widely used to manage complex medication regimes, and help remind...

Patients should be asked if they are wearing a transdermal patch prior to a magnetic resonance imaging (MRI) scan Background A recent case of possible fentanyl toxicity in a patient wearing a transdermal patch during an MRI highlighted the safety issues associated with medication patches in MR...

At the end of February this year all CDHB hospitals switched from using iv infusions of omeprazole to iv intermittent boluses in the treatment regimen for upper gastrointestinal bleeding. This decision (which involved General Surgery, Gastroenterology, Clinical Pharmacology, Pharmacy and the Emer...

The discharge prescribing of opioid analgesics, particularly oxycodone, has caused concern nationally and locally. Canterbury District Health Board (CDHB) encourages the prescribing of morphine in preference to oxycodone in most situations. In New Zealand the number of community prescriptions for...

Rivaroxaban (Factor Xa inhibitor) and dabigatran etexilate (a direct thrombin inhibitor) are alternatives to warfarin for oral anticoagulation, and to low-molecular weight heparins (LMWH) post-orthopaedic surgery. This bulletin discusses the use of rivaroxaban - important characteristics and pote...